Which has grown faster, NTLA or NVCR?

Over the past five years, NTLA grew revenue faster — NTLA at a 7.31% CAGR versus NVCR at 5.12%.

How have NTLA and NVCR total returns compared?

Over the past 10 years, NTLA delivered -3.03% and NVCR delivered 5.67% annualized total return. Past performance doesn't predict future results.

Intellia Therapeutics, Inc. (NTLA) vs Novocure Ltd (NVCR)

A side-by-side comparison of Intellia Therapeutics, Inc. and Novocure Ltd across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

NTLA

Intellia Therapeutics, Inc.

$1.69B

$12.12HealthcareDelayed quote: Oct 6, 2026, 1:30 PM EDT

NVCR

Novocure Ltd

$1.79B

$15.39HealthcareDelayed quote: Oct 6, 2026, 1:30 PM EDT

Total return — NTLA vs NVCR

growth of $100 · dividends reinvested · last 10y

NTLA -26.5% (-3.0%/yr)NVCR +73.5% (+5.7%/yr)NVCR compounded faster over this window

NTLA NVCR

NTLA vs NVCR: by the numbers

•NVCR is the larger company ($1.79B vs $1.69B market cap).
•Both run net losses; NVCR's is the smaller (-21.25% vs -672.16% net margin).
•NTLA grew revenue faster over the past five years (7.31% vs 5.12% CAGR).

Metrics side by side

Valuation

Metric	NTLA	NVCR
P/S ratio	28.46	2.56
P/B ratio	2.33	5.30

Profitability

Metric	NTLA	NVCR
Gross margin	76.47%	76.13%
Operating margin	-651.67%	-22.08%
Net margin	-672.16%	-21.25%
ROE	-54.96%	-43.94%
ROIC	-54.45%	-26.88%

Growth (annualized)

Metric	NTLA	NVCR
Revenue CAGR (5Y)	7.31%	5.12%
Total return CAGR (5Y)	-37.13%	-32.71%

Frequently asked

Which has grown faster, NTLA or NVCR?: Over the past five years, NTLA grew revenue faster — NTLA at a 7.31% CAGR versus NVCR at 5.12%.
How have NTLA and NVCR total returns compared?: Over the past 10 years, NTLA delivered -3.03% and NVCR delivered 5.67% annualized total return. Past performance doesn't predict future results.

Go deeper

Full NTLA analysis Full NVCR analysis Interactive comparison tool

Dig into the metrics

Intellia Therapeutics ROE Novocure ROE Intellia Therapeutics operating margin Novocure operating margin Intellia Therapeutics revenue growth Novocure revenue growth Intellia Therapeutics free cash flow Novocure free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.